Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: ixekizumab

EU Approves Marketing for Ixekizumab in Adults with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 7, 2018

In its second indication in the EU, ixekizumab has been approved by the European Commission to treat adults with active psoriatic arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:EuropeEuropean UnionixekizumabPsoriatic Arthritisskin

Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2018

In the U.S., a new formulation and an ergonomic delivery system for single doses of etanercept are now available for RA patients…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:auto-injectoretanerceptixekizumabPsoriatic ArthritisRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)

Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails

Reuters Staff  |  June 1, 2017

NEW YORK (Reuters Health)—The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial. The SPIRIT-P2 trial joins the earlier phase 3 SPIRIT-P1 trial, which showed that ixekizumab was safe and effective in PsA patients not previously treated…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:interleukin-17A inhibitorixekizumabphase 3 SPIRIT-P2 trialPsoriatic ArthritisTNF inhibitor

Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results

Michele B. Kaufman, PharmD, BCGP  |  October 12, 2016

A study found that ixekizumab decreases disease activity and increases physical function in biologic-naive patients with active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumab-attoIL-17ixekizumabPsoriatic Arthritis

Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016

Thomas R. Collins  |  September 12, 2016

LONDON—Results from the extension phase of a Phase 3 trial for the IL-17A inhibitor ixekizumab in psoriatic arthritis (PsA) show that patients started on placebo, adalimumab and ixekizumab continued to show improvements in arthritis, dactylitis and ethesitis, said Philip Mease, MD, a rheumatologist at Swedish Medical Center University of Washington in Seattle.1 Dr. Mease presented the…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsPsoriatic ArthritisResearch Rheum Tagged with:adalimumabDisease-modifying antirheumatic drugs (DMARDs)EULAREuropean League Against RheumatismixekizumabPsoriatic ArthritisResearchsecukinumabTreatment

Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis

Michele B. Kaufman, PharmD, BCGP  |  September 9, 2016

Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on…

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:drug updateixekizumaboutcomeproductivityPsoriasisResearchRheumatoid arthritisrheumatologySafetytrialvobarilizumab

Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  August 10, 2016

In three clinical trials, ixekizumab proved more effective than placebo or etanercept at increasing the work attendance and productivity of patients with plaque psoriasis…

Filed under:Biologics/DMARDsDrug UpdatesWorkforce Tagged with:ixekizumabplaque psoriasisproductivityPsoriasis

OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2016

Clinical trials have begun to determine if disodium zoledronate tetrahydrate is safe and effective for treating pain in patients with knee osteoarthritis. The FDA has approved the use of ixekizumab for the treatment of plaque psoriasis. And a study has shown that patients with SLE treated with belimumab may be able to decrease steroid use…

Filed under:Biologics/DMARDsDrug Updates Tagged with:belimumabdisodium zoledronate tetrahydrateFDAFood and Drug AdministrationixekizumabKnee Osteoarthritis (OA)Painplaque psoriasissystemic lupus erythematosus (SLE)

U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis

Reuters Staff  |  March 25, 2016

(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis. The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said. Taltz works by blocking interleukein-17A, a…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug Administrationixekizumabplaque psoriasisskin

Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity

Michele B. Kaufman, PharmD, BCGP  |  March 23, 2016

In a 52-week clinical trial, patients with plaque psoriasis who took secukinumab achieved greater sustained skin clearance then those taking ustekinumab. Also, three clinical trials showed ixekizumab improves work productivity in patients with plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:ixekizumabplaque psoriasisproductivitysecukinumabskinustekinumabworkplace

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences